Focused On-demand Library for Receptor-type tyrosine-protein phosphatase H

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9HD43

UPID:

PTPRH_HUMAN

Alternative names:

Stomach cancer-associated protein tyrosine phosphatase 1; Transmembrane-type protein-tyrosine phosphatase type H

Alternative UPACC:

Q9HD43; C9JCH2; Q15426; Q2NKN9; Q2NKP0

Background:

Receptor-type tyrosine-protein phosphatase H, also known as Stomach cancer-associated protein tyrosine phosphatase 1 and Transmembrane-type protein-tyrosine phosphatase type H, plays a crucial role in cell growth, motility, and apoptotic cell death. It mediates dephosphorylation of focal adhesion-associated substrates, negatively regulating integrin-promoted signaling processes. This protein is pivotal in inhibiting cell survival signaling pathways and activating caspase-dependent proapoptotic pathways.

Therapeutic significance:

Understanding the role of Receptor-type tyrosine-protein phosphatase H could open doors to potential therapeutic strategies. Its involvement in cell survival signaling and apoptotic pathways makes it a promising target for developing treatments for diseases where these processes are dysregulated.